The pharmacological management of migraine, part I overview and abortive therapy

P and T

Volumn 33, Issue 7, 2008, Pages 404-416

  DeMaagd, George ^a  

^a UNION UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; ALMOTRIPTAN; ANACIN; ANALGESIC AGENT; ANTIEMETIC AGENT; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; BUTORPHANOL TARTRATE; CHLORPROMAZINE; COCODAMOL; DEXTROPROPOXYPHENE; DICLOFENAC POTASSIUM; ERGOT DERIVATIVE; EXCEDRIN; FROVATRIPTAN; IBUPROFEN; KETOROLAC; METOCLOPRAMIDE; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PERCOCET; PERCODAN; PROCHLORPERAZINE MALEATE; RIZATRIPTAN; SEROTONIN AGONIST; SUMATRIPTAN SUCCINATE; UNINDEXED DRUG; ZOLMITRIPTAN;

CLINICAL TRIAL; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MIGRAINE; PATHOPHYSIOLOGY; REVIEW;

EID: 49249131554     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (252)

1. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001;17(Suppl 1)S4-S12.
2. Rozen TD, Swanson JW, Stang PE, et al. Increasing incidence of medically recognized migraine headache in a United States population. Neurology 1999;53(7):1468-1473.
3. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992;267(1):64-69.
4. Goldberg LD. The cost of migraine and its treatment. Am J Manag Care 2005;11:S62-S67.
5. Adelman JU, Adelman LC, Freeman MC, et al. Cost considerations of acute migraine treatment. Headache 2004;44:271-285.
6. May A, Goadsby PJ. The trigeminovascular system in humans: Pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999;19:115-127.
7. van de Ven RC, Kaja S, Plomp JJ, et al. Genetic models of migraine. Arch Neurol 2007;64:643-646.
8. Hamel E. Serotonin and migraine: Biology and clinical implications. Cephalalgia 2007;27(11):1293-1300.
9. Cady R, Dodick D, Levine H, et al. Sinus headache: A neurology, otolaryngology, allergy, and primary care consensus on diagnosis and treatment. Mayo Clin Proc 2005:80(7):908-916.
10. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 2001;41:638-645.
11. Headache Classification Subcommittee of the International Headache Society. International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004;24(Suppl.1):1-151.
12. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56(5):811-824.
13. Lipton RB, Bigal ME, Amatniek JC, et al. Tools for diagnosing migraine and measuring its severity. Headache 2004;44:387-398.
14. Giffin NJ, Ruggiero L, Lipton RB, et al. Premonitory symptoms in migraine: An electronic diary study. Neurology 2003;60:935-940.
15. Tepper SJ. Tailoring management strategies for the patient with menstrual migraine: Focus on prevention and treatment. Headache 2006;46(Suppl 2):S61-S68.
16. Rains JC, Poceta JS, et al. Headache and sleep disorders: Review and clinical implications for headache management. Headache 2006;46(9):1344-1363.
17. Tietjen GE, Brandes JL, Digre KB, et al. High prevalence of somatic symptoms and depression in women with disabling chronic headache. Neurology 2007;68:134-140.
18. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: Current understanding and treatment. N Engl J Med 2002;346:257-270.
19. Adelman JU, Adelman RD. Current options for the prevention and treatment of migraine. Clin Ther 2001;23(6):772-788.
20. Blau JN. Thavapalan M. Preventing migraine: A study of precipitating factors. Headache 1988;28:481-483.
21. Guarniert P, Radnitz CL, Blanchard EB. Assessment of dietary risk factors in chronic headache. Biofeedback Self-Regulation 1990;15(1):15-25.
22. Bogucki A. Studies on nitroglycerin and histamine provoked cluster headache attacks. Cephalalgia 1989;22:90-153.
23. Sensenig J, Johnson M, Staverosky T. Treatment of migraine with targeted nutrition focused on improved assimilation and elimination. Altern Med Rev 2001;6(5):488-494.
24. Bigal ME, Lipton RB. The preventive treatment of migraine. Neurologist 2006;12:204-213.
25. Earles J, Folen RA, James LC. biofeedback using telemedicine: Clinical applications and case illustrations. Behav Med 2001;27:77-82.
26. Sorbi M, Tellegen B, Du Long A. Long-term effects of training in relaxation and stress. Coping in patients with migraine: A three-year follow-up. Headache 1989;29:111-112.
27. Sheffield MM. Psychosocial interventions in the management of recurrent headache disorders: Policy considerations for implementation. Behav Med 1994;20:74-77.
28. Melchart D, Linde K, Fischer P, et al: Acupuncture for recurrent headaches: A systematic review of randomized controlled trials. Cephalalgia 1999;19:779-786.
29. Streng A, Linde K, Hoppe A. Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis. Headache 2006;46(10):1492-1502.
30. Pelka RB, Jaenicke C, Gruenwald J. Impulse magnetic-field therapy for migraine and other headaches: A double-blind placebo-controlled study. Adv Ther 2001;18(3):101-109.
31. Norton D. Migraine and photic stimulation: Report on a survey of migraineurs using flickering light therapy. Complement Ther Nurs Midwifery 2000;6:138-142.
32. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the non-pharmacological management of migraine in clinical practice. Canadian Headache Society. Can Med Assoc J 1998;159(1):47-54.
33. Goslin RE, Gray RN, McCrory DC, et al. Behavioral and physical treatments for migraine headache. Technical review 2. February 1999. Prepared for Agency for Health Care Policy and Research, Contract No. 290-94-2025. Available at: www.clinpol.mc.duke.edu./Pubs/Publications/Behavioral_Manuscript.pdf. Accessed August 2007.
34. Holroyd KA, Penzien DB. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache: A meta-analytic review of clinical trials. Pain 1990;42:1-13.
35. Diamond ML, Wenzel RG, Nissan. Optimizing migraine therapy: Evidence-based and patient-centered care. Expert Rev Neurother 2006;6(6):911-919.
36. Silberstein SD, for the U.S. Headache Consortium. Practice Parameter: Evidence-Based Guidelines for Migraine Headache (An Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-762.
37. Educational Resources and Headache Diaries, National Headache Foundation. Available at: www.headaches.org. Accessed August 2007.
38. Weitzel KW. Thomas ML, Small RE. Migraine: A comprehensive review of new treatment options. Pharmacotherapy 1999;19(8):957-973.
39. Diamond S, Bigal ME, Silberstein S. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-363.
40. Wenzel RG, Lipton RB, Diamond ML, et al. Migraine therapy: A survey of pharmacists' knowledge, attitudes, and practice patterns. Headache 2005;45:47-52.
41. King DS, Herndon KC. Headache disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, et al., eds. Pharmacotherapy: A Pathophysiologic Approach. 6th ed. Norwalk, CT: Appleton & Lange; 2005:1105-1121.
42. Alldredge BK. Neurologic disorders: headache. In: Koda-Kimble MA, Young YL, eds. Applied Therapeutics: The Clinical Use of Drugs, 8th ed. Baltimore: Lippincott Williams & Wilkins; 2005:52-1-52-27.
43. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112:135-140.
44. Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what migraine patients want from therapy? Headache 1999;39(Suppl2):S20-S26.
45. Malik SN, Hopkins M, Young W, Silberstein SD. Acute migraine treatment: Patterns of use and satisfaction in a clincal population. Headache 2006;46:773-780.
46. Remington TL. Headache. In: Berardi RR, McDermott JH, Newton GD, et al., eds. Handbook of Nonprescription Drugs, 14th ed. New York: McGraw-Hill; 2006:69-90.
47. Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: Literature review and recommendations. Pharmacotherapy 2003;23(4):494-505.
48. Lipton RB, Baggish JS, Stewart WF, et al. Efficacy and safety of acetaminophen in the nonprescription treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 2000;160:3486-3492.
49. Larson BH, Christiansen LV, Andersen B, et al. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine. Acta Neurol Scand 1990;81(5):464-467.
50. Hamalainen ML, Hoppu K, Valkeila E, et al. Ibuprofen or acetaminophen for the acute treatment of migraine in children: A double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48(1):103-107.
51. Lipton, RB, Goldstein J, Baggish JS, et al. Aspirin is efficacious for the treatment of acute migraine. Headache 2005;45(4):283-292.
52. Diener HC, Lampl C, Reimnitz P et al. Aspirin in the treatment of acute migraine attacks. Exp Rev Neurother 2006;6(4):563-573.
53. MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine. Headache 2002;42(4):249-255.
54. Lange R, Schwarz JA, Hohn M. Acetylsalicylic acid effervescent 1000 mg in acute migraine attacks. Cephalalgia 200;20:663-667.
55. Diener HC, Bussone G, de Liano H, et al. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan, and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24(11):947-954.
56. Diener HC, Eikermann A, Gessner U, et al. Efficacy of 1000 mg effervescent acetylsalicylic acid and sumatriptan in treating migraine symptoms. Eur Neurol 2004;52:50-56.
57. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998;55:210-217.
58. Goldstein J, Hoffman HD, Armellino JJ, et al. Treatment of severe, disabling migraine in an over-the-counter population of migraine sufferers: Results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 1999;19:684-691.
59. Silberstein SD, Armellino JJ, Hoffman HD, et al. Treatment of menstruation-associated migraine with the non-prescription combination of acetaminophen, aspirin, and caffeine: Results from three randomized, placebo-controlled studies. Clin Ther 1999;21(3):475-491.
60. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin and caffeine in combination versus ibuprofen for acute migraine: Results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 2006;6(3):444-453.
61. Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: Results from the ASSET trial. Headache 2005;45:973-982.
62. Diener HC, Katasarva Z. Analgesic/abortive overuse and misuse in chronic daily headache. Curr Pain Headache Rep 2001;5:545-550.
63. Mathew NT, Kurman R, Perez F. Drug-induced refractory headache: Clinical features and management. Headache 1990;13:634-638.
64. Kellstein DE, Lipton RB, Geetha R, et al. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double blind, placebo-controlled, dose-ranging study. Cephalalgia 2000;20:233-243.
65. Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache: A randomized controlled trial. Headache 2001;41:665-679.
66. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992;12(3):169-171.
67. Lewis DW, Kellstein D, Dahl G. Children's ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002;42(8):780-786.
68. Andersson PG, Hinge HH, Johansen O, et al. Double-blind study of naproxen vs. placebo in the treatment of acute migraine attacks. Cephalalgia 1989;9(1):29-32.
69. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia 1985;5(1)5-10.
70. Nestvold K, Kloster R, Partinen M, et al. Treatment of acute migraine attack: Naproxen and placebo compared. Cephalalgia 1985;5(2):115-119.
71. Massiou H, Serrurier D, Lasserre O, et al. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: A double-blind study versus placebo. Cephalalgia 1991;11:59-63.
72. Karachalios GN, Fotiadou A, Chrisikos N, et al. Treatment of acute migraine attack with diclofenac sodium: A double-blind study. Headache 1992;32:98-100.
73. Dahlof C, Bjorkman R. Diclofenac-K (50 mg and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia 1993;13:117-123.
74. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine. Neurology 2002;58:1660-1665.
75. Harden RN, Carter TD, Gilman CS, et al. Ketorolac in acute headache management. Headache 1991;31:463-464.
76. Nebe J, Heier M, Diener HC. Low-dose ibuprofen in self-medication of mild to moderate headache: A comparison with acetylsalicylic acid and placebo. Cephalalgia 1995;15:31-35.
77. Treves TA, Streiffler M, Korczyn AD. Naproxen sodium versus ergotamine tartrate in the treatment of acute migraine attacks. Headache 1992;32(6):280-282.
78. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen for the acute treatment of migraine. Headache 2005;45(8):983-991.
79. Stronks DL, Tulen JH, Bussmann HB, et al. Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: A randomized, double-blind, double-dummy, crossover study. Headache 2003;43(8):845-852.
80. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006;67:497-499.
81. Pradalier A, Rancurel G, Dordain G, et al. Acute migraine attack therapy: Comparison of naproxen sodium and ergotamine tartrate compound. Cephalalgia 1985;5:107-113.
82. Sargent JD, Baumel B, Peters K, et al. Aborting a migraine attack: Naproxen sodium vs ergotamine plus caffeine. Headache 1988;28:263-266.
83. Diclofenac-K and the Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison with oral sumatriptan and placebo. Cephalalgia 1999;19:232-240.
84. Winner P, Cady RK, Ruoff GE, et al. Twelve-month tolerability and safety of sumatriptan and naproxen sodium for the treatment of acute migraine. Mayo Clin Proc 2007;82(1):61-68.
85. Peroutka S, Lyon JA, Swarbrick J, et al. Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: A randomized, double-blind, crossover study. Headache 2004;44:136-141.
86. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin (Migravess) versus effervescent aspirin or placebo for migraine attacks: A double blind study. Cephalalgia 1984;4:107-111.
87. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives; ethanol. In: Goodman Gilman A, Rall TW, Hardman JG, Limbird LE, eds. The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill; 1990:348-382.
88. Silberstein SD, McCrory DC. Butalbital in the treatment of headaches: History, pharmacology, and efficacy. Headache 2001;41:953-967.
89. Sellers EM, Hoornweg K, Busto UE, et al. Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999;6:18-35.
90. McLean W, Boucher EA, Brennan M, et al. Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Can J Clin Pharmacol. 2000;7(4):191-197.
91. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: www.aan.com/public/practiceguidelines/03.pdf/. Accessed August 2007.
92. Capobianco DJ, Swanson JW, Dodick DW. Medication-induced (analgesic rebound) headache: Historical aspects and initial descriptions of the North American experience. Headache 2001;41:500-502.
93. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin 1997;15(1):167-186.
94. Panconesi A, Anselmi B, Franchi G. Increased adverse effects of opiates in migraine patients. Cephalalgia 1995;15(2):159-160.
95. Boureau F, Joubert JM, Lasserre V, et al. Double-blind comparison of an acetaminophen 400 mg-codeine 25 mg combination versus aspirin 1000 mg and placebo in acute migraine attack. Cephalalgia 1994;14:156-161.
96. Adam EI. A treatment for the acute migraine attack. J Int Med Res 1987;15:71-75.
97. Carasso RI, Yehuda S. The prevention and treatment of migraine with an analgesic combination. Br J Clin Pract 1984;38:25-27.
98. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989;18(4):361-365.
99. Gallagher MR. Emergency treatment of intractable migraine. Headache 1985;26:74-75.
100. Fisher MA, Glass S. Butorphanol (Stadol): A study in problems of current drug information and control. Headache 1997;48:1156-1160.
101. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995;35:65-69.
102. Biondi DM. Opioid resistance in chronic daily headache: A synthesis of ideas from the bench and bedside. Curr Pain Headache Rep 2003;7(1):67-75.
103. Edmeads J. Analgesic-induced headaches: An unrecognized epidemic. Headache 1990:614.
104. Diamond S, Medina JL, Isometheptene: A non-ergot drug in the treatment of migraine. Headache 1975;15:211-213.
105. Yuill GM, Swinburn WR, Liversedge LA. A double-blind cross-over trial of isometheptene mucate compound and ergotamine in migraine. Br J Clin Pract 1972;26:76-79.
106. Diamond S. Treatment of migraine with isometheptene, acetaminophen, and dichloralphenazone combination: A double-blind, crossover trial. Headache 1976;15:282-287.
107. Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isomemeptene mucate, dichloralphenazone with acetaminophen, and sumatriptan succinate in the treatment of migraine. Headache 2001;41(4):391-398.
108. Bigal ME, Rapoport AM, Sheftell FD, et al. Transforming migraine and medication overuse in a tertiary headache centre: Clinical characteristics and treatment. Cephalalgia 2004;24(6):4483-4490.
109. Micieli G, Manzoni GC, Granella F, et al. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener HC, Wilkinson M, eds. Drug-Induced Headache. Heidelberg, Germany: Springer-Verlag; 1988:20-28.
110. Ferrari A, Savino G, Gallesi D, et al. Effects of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine on the disposition of its components in chronic headache patients. Pharmacol Res 2006;54:142-149.
111. Paemeleire K, Crevits L, Goadsby PJ, et al. Practical management of medication-overuse headache. Acta Neurol Belg 2006;106(2):43-51.
112. Freitag FG, Lake A, Lipton R, et al. Inpatient treatment of headaches: An evidence-based assessment. Headache 2004;44:342-360.
113. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995-997.
114. Smith RS. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache 2002;42:175-177.
115. Zed PJ, Loewen PS, Robinson G. Medication-induced headache: Overview and systematic review of therapeutic approaches. Ann Pharmacother 1999;33:61-72.
116. Humphrey PP, Feniuk W, Perren MJ et al. Serotonin and migraine. Ann NY Acad Sci 1990;600:587-598.
117. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytriptamine (serotonin) . Pharmacol Rev 1994;46:157-203.
118. 1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-105.
119. 1F) receptor agonist LY334370 for acute migraine: A randomized controlled trial. Lancet 2001;358:1230-1234.
120. Peroutka SJ. Developments in 5-hydroxytriptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-839.
121. Siberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache 1997;36(Suppl 1):S15-S25.
122. Siberstein SD. Serotonin (5-HT) and migraine. Headache 1994;34:408-417.
123. Peroutka SJ. 5-Hydroxytriptamine receptor subtypes and the pharmacology of migraine. Neurology 1993;43(Suppl 3):S34-S38.
124. Borne RF. Serotonin: the neurotransmitter for the 90's. Drug Top 1994;10:108.
125. 1D receptor agonism predicts antimigraine efficacy. Headache 1991;31(4):228-231.
126. 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991;11(4):165-168.
127. Scott AK. Dihydroergotamine: A review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol 1992;15(4):289-296.
128. Goldstein J. Ergot pharmacology and alternative delivery systems for ergotamine derivatives. Neurology 1992;42(Suppl 2):45-46.
129. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: A review. Curr Pain Headache Rep 2003;7(1):55-62.
130. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56.
131. Ward TN, Scott G. Dihydroergotamine suppositories in a headache clinic. Headache 1991;31(7):465-466.
132. Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res 1986;VI(1):11-13.
133. Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: Current perspectives. Headache 1997;37(Suppl 1):S42-S45.
134. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-171.
135. Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency treatment of acute migraine headaches. Am Emerg Med 1998;32:129-138.
136. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs. subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-184.
137. Colman I, Brown MD, Innes GD, et al. Parenteral dihydroergotamine for acute migraine headaches: A systemic review of the literature. Ann Emerg Med 2005;45(4):393-401.
138. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol 1996;53:1285-1291.
139. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology 1994;44:447-453.
140. Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache 1995;35:177-184.
141. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47:361-365.
142. Migranal (dihydroergotamine), package insert. East Hanover, NJ: Novartis; December 2001.
143. Schulman EA, Rosenberg SB. Claudication: An unusual side effect of DHE administration. Headache 1991;31(4):237-239.
144. Peters GA, Horton BT. Headache with special reference to the excessive use of ergotamine preparations and withdrawal effects. Mayo Clin Proc 1951;26:153-161.
145. Saper J. Ergotamine tartrate addiction. Mich Pharm 1986;4-8.
146. Saper J. Ergotamine dependency: A review. Headache 1987;27:435-438.
147. Saper J, Jones JM. Ergotamine tartrate dependency: Features and possible mechanisms. Clin Neuropharmacol 1986;9(3):244-256.
148. Imitrex (sumatriptan), package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006.
149. Zomig, ZMT, Nasal Spray (zolmitriptan), package insert. Wilmington, DE: AstraZeneca; 2006.
150. Amerge (naratriptan), package insert. Research Triangle Park, NC: GlaxoSmithKline; 2006.
151. Maxalt, Maxalt-MLT (rizatriptan), package insert Whitehouse Station, NJ: Merck & Co.; 2007.
152. Axert (almotriptan), package insert. Raritan, NJ: Ortho-McNeil; 2006.
153. Frova (frovatriptan), package insert. Chadds Ford, PA: Endo; 2005.
154. Relpax (eletriptan), package insert. NewYork: Pfizer; 2006.
155. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain. Ann Neurol 2004;55:27-36.
156. Coulter DM, Passier JL, Clark DW, et al. Activation of pain by sumatriptan. Headache 2003;43(9):994-999.
157. 1B/1D receptor agonists. Arch Neurol 2002;59(7):1084-1088.
158. Durham P, Russo A. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther 2002;94(1-2):77-92.
159. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202-206.
160. 1 like receptor. Cephalalgia 1992;12:202-205.
161. Humphrey A, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-410.
162. Fullerton T, Gengo FM. Sumatriptan: A selective 5-hydroxytriptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother 1992;26:800-807.
163. 1B/1D agonists. Arch Intern Med 2001;161:2545-2553.
164. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics, and efficacy. Drugs 2000;50:1259-1287.
165. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Clin Ther 2000;22:981-989.
166. Dixon R, French S, Kemp J, et al. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J Clin Pharmacol 1998;38:694-701.
167. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999;39:1203-1211.
168. Pascual J, Munoz P. Correlation between lipophilicity and triptan outcomes. Headache 2005;45(1):3-6.
169. Ferrari MD, Roon KI Lipton RB, et al. Oral triptans in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668-1675.
170. Dahlof CG, Pascual J, Dodick DW, et al. Efficacy, speed of action, and tolerability of almotriptan in the acute treatment of migraine: Pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26(4):400-408.
171. Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebo-controlled trial. Headache 2007;47(4):511-518.
172. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: Systemic review of randomized controlled trials. J Clin Pharm Ther 2005;30(6):521-532.
173. Ahonen K, Hamalainen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006;67(7):1135-1140.
174. Tepper SJ, Cady R, Dodick D, et al. Oral sumatriptan for the acute treatment of probable migraine: First randomized, controlled trial. Headache 2006;46(1):115-124.
175. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115(1):34-40.
176. Mandema JW, Cox E, Alderman J, et al. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain. Cephalagia 2005;25(9):715-725.
177. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache 2005;45(7):874-882.
178. Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci 2006;27:S123-S129.
179. Goldstein J, Tiseo PT, Albert KS, et al. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006;46(7):1142-1150.
180. Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: A double-blind, randomized, placebo-controlled study in patients with a previous poor response to sumatriptan 50 mg. Curr Med Res Opin 2005;21(10):1603-1610.
181. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans: Review of four trials. Cephalalgia 2006;26(2):98-106.
182. Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26(3):246-256.
183. Diez FI, Straube A, Zanchin G. Patient preference in migraine therapy: A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol 2007;254(2):242-249.
184. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006;67(3):497-499.
185. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs. sumatriptan for the emergency department treatment of migraines. Neurology 2005;64(3):463-468.
186. Friedman BW, Hochberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache 2006;46(6):934-941.
187. Martin VT, Loder E, Taylor K, et al. Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: Results from a multiple attack study. Cephalalgia 2005;25(9):726-734.
188. Pascual J, Garcia-Monco C, Roig C, et al. Rizatriptan 10-mg wafer versus usual non-triptan therapy for migraine: Analysis of return to function and patient preference. Headache 2005;45(9):1140-1150.
189. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA 2007;297(13):1443-1454.
190. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies. Cephalalgia 1999;19:769-778.
191. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol 1991;238:S66-S69.
192. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112:135-140.
193. Dodick D, Lipton RB, Martin V, et al. Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT Agonists) in the Acute Treatment of Migraine. Headache 2004;44(5):414-425.
194. Maassen VanDen Brink A, Reekers M, Bax WA, et al. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
195. Laine K, Raasakka T, Mantynen J, et al. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511-512.
196. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006;67(7):1128-1134.
197. Pacheco-Coronado R, McMullan PW, Galbut BH, et al. Myocardial infarction after taking zolmitriptan. Yale J Biol Med 2005;78(3):147-150.
198. Arora A, Arora S. Spontaneous splenic infarction associated with sumatriptan use. J Headache Pain 2006;7(4):214-216.
199. Fulton JA, Kahn J, Nelson LS, et al. Renal infarction during the use of rizatriptan and zolmitriptan: Two case reports. Clin Toxicol 2006;44(2):177-180.
200. Repaka A, Wenger J, Sitaraman SV. A case of sumatriptan-induced intestinal ischemia. J Gastroenterol 2006;41(2):177-178.
201. Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001:85(4):959-970.
202. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med 2005;228(Suppl 1):36S-44S.
203. Hilaire ML, Cross LB, Eichner SF. Treatment of migraine headaches with sumatriptan in pregnancy. Ann Pharmacother 2004;38(10):1726-1730.
204. Gardner DM, Lynd LD. Sumatriptan contraindications and serotonin syndrome. Ann Pharmacother 1998;32:33-38.
205. Shapiro RE, Tepper SJ, et al. The serotonin syndrome, triptans and the potential for drug-drug interactions. Headache 2007;47:266-269.
206. Wooltorton E. Triptan migraine treatment and antidepressants: Risk of serotonin syndrome. Can Med Assoc J 2006;175(8):874.
207. Eadie M. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15(2):105-118.
208. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999;39:192-199.
209. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84-112.
210. 1b/1d agonist Differential effects of propranolol, nadolol, and metoprolol. J Clin Pharmacol 2001;52:69-76.
211. Cutrer FM, Goadsby PJ, Ferrari MD, et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: A study of U.S. primary care physicians. Clin Ther 2004;26(9):1533-1545.
212. Dahlof CG. Non-oral formulations of triptans and their use in acute migraine. Curr Pain Headache 2005;9(3):206-212.
213. Diamond S, Freitag FG, Feoktistov A, et al. Sumatriptan 6 mg subcutaneous as an effective migraine treatment in patients with cutaneous allodynia who
214. Winner P, Adelman J, Aurora S, et al. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: Two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther 2006;28(10):1582-1591.
215. Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: A randomized, double-blind, placebo-controlled, acute study. Headache 2006;46(2):212-222.
216. Goadsby PJ, Yates R. Zolmitriptan intranasal: A review of the pharmacokinetics and clinical efficacy. Headache 2006;46(1):138-149.
217. Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002;22(2):101-106.
218. Dodick DW, Silberstein S, Daholf CG. Is there a preferred triptan? (Editorial) Headache 2002;42:1-7.
219. Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001;57:1377-1383.
220. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using acute intervention with oral triptans for migraine management. Int J Clin Pract 2007;60(6):698:706.
221. Sullivan JT, Preston KL, Testa MP, et al. Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 1992;52(6):635-642.
222. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001;57:1694-1698.
223. Jones J, Sklar D, Dougherty J, et al. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989;261(8):1174-1176.
224. Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics 2001;107(4):E62 and online.
225. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med 1995;26:541-567.
226. Jones J, Pack S, Chun E. Intramuscular prochlorperazine versus metoclopramide as single-agent therapy for the treatment of migraine headache. Ann Emerg Med 1995;26:541-546.
227. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs. intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998;5(6):573-576.
228. Jones EB, Gonzalez ER, Boggs JG, et al. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med 1994;24:237-241.
229. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med 2002;23(2):141-148.
230. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs. intravenous metoclopramide in acute migraine headache. Acad Emerg Med 1995;2(7):597-602.
231. Shrestha M, Singh R, Moreden JE, et al. Ketorolac vs. chlorpromazine in the treatment of acute migraine without aura: A prospective, randomized, double-blind trial. Arch Intern Med 1996;156(15):1725-1728.
232. Morgenstern LB, Huber JC, Luna-Gonzales H, et al. Headache in the emergency department. Headache 2001;41:537-541.
233. Wang SJ, Silberstein SD, Young WB, et al. Droperidol treatment of status migrainous and refractory migraine. Headache 1997;37(6):377-382.
234. Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headaches. Am J Emerg Med 2002;20:39-42.
235. Richman P, Reischel U, Ostrow A, et al. Droperidol: A novel therapy for the treatment of acute migraine headache. Am J Emerg Med 1999;17:398-400.
236. Fisher H. A new approach to emergency department therapy of migraine headaches with intravenous haloperidol: A case series. J Emerg Med 1995;13(1):119-122.
237. Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: Meta-analysis of randomised controlled trials. BMJ 2004;329(7479):1369-1373.
238. Happer JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991;31(8):523-524.
239. Schulman EA, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43(7):729-733.
240. Waberzinek G, Markova J, Mastik J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007;28(1):59-64.
241. Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache 2005;45(7):899-903.
242. Norton J. Use of valproate in status migraine. Headache 2000;40:755-757.
243. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976-980.
244. Mathew NT, Kailasam J. Repetitive intravenous administration of valproate sodium in intractable migraine: Comparison with intravenous dihydroergotamine (DHE) (Abstract). Cephalalgia 2000;20:351.
245. Goldner JA, Levitt LP. Treatment of complicated migraine with sublingual nifedipine. Headache 1987;27:484-486.
246. Yu W, Horowitz SH. Familial hemiplegic migraine and its abortive therapy with intravenous verapamil. Neurology 2001;57:1732.
247. Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs diclofenac sodium for the treatment of acute migraine attacks in emergency department: A prospective randomised, double-blind study. J Headache Pain 2005;6:143-148.
248. Cady RK, Schreiber CP, Beach ME, et al. Gelstat migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild phase. Med Sci Monit 2005;11(9):165-169.
249. Mapper J, Stanton J. The emergency treatment of acute migraine headache: A comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia 1991;11(Suppl 11):159-160.
250. Corbo J, Esses D, Bijur PE, et al. Randomized clinical trial of intravenous magnesium sulfate as an adjunctive medication for emergency department treatment of migraine headache. Ann Emerg Med 2001;38:621-627.
251. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management for prevention of migraine. U.S. Headache Consortium. Available at: www/aan.com/professional/practice. Accessed August 2007.
252. McCory DC, Matchar DB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache: Overview of program description and methodology. Available at www.aan.com/public/practiceguidelines/01.pdf. Accessed August 2007.